Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective

• Leslie A. Andritsos,
• Neil Dunavin,
• Gerard Lozanski,
• Jeffrey A. Jones,
• James S. Blachly,
• David M. Lucas,
• John C. Byrd,
• Eric Kraut,
• Michael R. Grever

Affiliations

Leslie A. Andritsos

The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH

Neil Dunavin

National Institutes of Health, National Heart, Lung, and Blood Institute, Hematology Branch, Bethesda, MD

Gerard Lozanski

The Ohio State University, Department of Pathology, Columbus, OH, USA.

Jeffrey A. Jones

The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH

James S. Blachly

The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH

David M. Lucas

The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH

John C. Byrd

The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH

Eric Kraut

The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH

Michael R. Grever

The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH